SwePub
Tyck till om SwePub Sök här!
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:1872 7980 "

Sökning: L773:1872 7980

  • Resultat 51-60 av 96
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
51.
  • Liu, D. L, et al. (författare)
  • Tumour vessel damage resulting from laser-induced hyperthermia alone and in combination with photodynamic therapy
  • 1997
  • Ingår i: Cancer Letters. - 1872-7980. ; 111:1-2, s. 157-165
  • Tidskriftsartikel (refereegranskat)abstract
    • This study examined tumour vessel injury resulting from laser-induced hyperthermia alone and in combination with photodynamic therapy (PDT) in the treatment of rat liver tumours by means of scanning electron microscopy. A total of 18 Wistar rats were divided into three groups, Group I (six animals) underwent hyperthermia for 15 min (15-min hyperthermia). Group II (six animals) underwent hyperthermia for 30 min (30-min hyperthermia). Group III (six animals) received the combined treatment of PDT and 30-min hyperthermia. For PDT, delta-amino laevulinic acid at a dose of 60 mg/kg of body weight was intravenously administered 60 min before irradiation at 635 nm. The morphological results indicated that 15-min hyperthermia gave rise to an increase in permeability of the vessels in the treated tumour. Thirty-min hyperthermia caused extreme oedema of vascular endothelial cells and restrictive openings of tumour branch vessels. The combined therapy of PDT and hyperthermia destroyed tumour vasculature. Large breaks of the inner wall of the treated tumour vessels were deeply involved in the basement membrane of the vessel. The results indicate that there may be a close link between inhibition of tumour growth and degree of damage to tumour vessels. (C) 1997 Elsevier Science Ireland Ltd.
  •  
52.
  • Liu, Fuli, et al. (författare)
  • Ursodeoxycholic acid differentially affects three types of sphingomyelinase in human colon cancer Caco 2 cells.
  • 2006
  • Ingår i: Cancer Letters. - : Elsevier BV. - 1872-7980 .- 0304-3835. ; 235:1, s. 141-146
  • Tidskriftsartikel (refereegranskat)abstract
    • We investigated the effects of UDCA on sphingomyelinase (SMase) in Caco 2 cells cultured in monolayer and polarized conditions. Alkaline SMase activity was high in polarized cells whereas. acid and neutral SMase activities were high in monolayer cells. In polarized cells, UDCA increased alkaline SMase expression and caspase 3 activity but had no effect on acid and neutral SMases. In monolayer cells, UDCA reduced both acid and neutral SMase activities, inhibited cell proliferation, but had little effect on alkaline SMase and caspase 3 activities. In conclusion, UDCA differentially affects SMasc activity, cell proliferation, and apoptosis in colonic cells depending on the cell conditions. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
  •  
53.
  • Liu, Hua, et al. (författare)
  • Low dose Zebularine treatment enhances immunogenicity of tumor cells
  • 2007
  • Ingår i: Cancer Letters. - : Elsevier BV. - 1872-7980 .- 0304-3835. ; 257:1, s. 107-115
  • Tidskriftsartikel (refereegranskat)abstract
    • Strategy: We have investigated how alterations in gene expression induced by the demethylating drug Zebularine affect the immune response tumor cells elicit. The rational has been to treat syngeneic rat colon cancer cells with Zebularine at different concentrations and then use these cells to study gene expression of different genes involved in cancer immunogenicity. Gene expressions were monitored by semi-quantitative PCR and real-time PCR. Results: Intriguingly there was a large increase in the production of indoleamine 2,3-dioxygenase (IDO) after treatment with 100 mu M Zebularine as compared with untreated tumor cells, whereas treatment with 20 mu M Zebularine caused a significant decrease of the IDO production. After immunization with syngeneic tumor cells, spleen cells were isolated and restimulated in vitro with irradiated tumor cells. Immune reactivity was measured by proliferation, and production of interferon gamma and interleukinl0. The immunogenicity of tumor cells treated in vitro with a low dose of Zebularine increased, whereas it decreased after high dose exposure. The inhibition of immunogenicity by 100 mu M Zebularine was shown to be counteracted by the IDO inhibitor I methyl-tryptophan (1MT), confirming that this effect of Zebularine is mainly caused by IDO induction. Differences using Zebularine-treated or non-treated cells for in vitro restimulation were marginal. Conclusion: Low dose treatment with Zebularine (20 mu M) decreases the production of the immunosuppressive IDO from rat colon cancer cells and enhances their immunogenicity, whereas high dose Zebularine treatment (100 mu M) enhances the IDO production from the cancer cells and suppresses their immunogenicity. This immunosuppression should be considered when cancer is treated with Zebularine or drugs acting in a similar way. (C) 2007 Published by Elsevier Ireland Ltd.
  •  
54.
  • Lohr, Miriam, et al. (författare)
  • The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer
  • 2013
  • Ingår i: Cancer Letters. - : Elsevier BV. - 0304-3835 .- 1872-7980. ; 333:2, s. 222-228
  • Tidskriftsartikel (refereegranskat)abstract
    • A prognostic impact of immunoglobulin kappa C (IGKC) expression has been described in cancer. We analysed the influence of B-cell and plasma cell markers, as well as IGKC expression, in non-small lung cancer (NSCLC) using immunohistochemistry on a tissue microarray. IGKC protein expression was independently associated with longer survival, with particular impact in the adenocarcinoma subgroup. Moreover, a correlation was seen with CD138+ cells, but not with CD20. CD138 expression revealed a comparable association with survival. In conclusion, IGKC expression in stroma–infiltrating plasma cells is a prognostic marker in NSCLC, supporting emerging treatment concepts that exploit the humoral immune response.
  •  
55.
  • Lopez-Luque, Judit, et al. (författare)
  • Downregulation of Epidermal Growth Factor Receptor in hepatocellular carcinoma facilitates Transforming Growth Factor-beta-induced epithelial to amoeboid transition
  • 2019
  • Ingår i: Cancer Letters. - : ELSEVIER IRELAND LTD. - 0304-3835 .- 1872-7980. ; 464:Nov, s. 15-24
  • Tidskriftsartikel (refereegranskat)abstract
    • The Epidermal Growth Factor Receptor (EGFR) and the Transforming Growth Factor-beta (TGF-beta) are key regulators of hepatocarcinogenesis. Targeting EGFR was proposed as a promising therapy; however, poor success was obtained in human hepatocellular carcinoma (HCC) clinical trials. Here, we describe how EGFR is frequently downregulated in HCC patients while TGF-beta is upregulated. Using 2D/3D cellular models, we show that after EGFR loss, TGF-beta is more efficient in its pro-migratory and invasive effects, inducing epithelial to amoeboid transition. EGFR knock-down promotes loss of cell-cell and cell-to-matrix adhesion, favouring TGF-beta-induced actomyosin contractility and acquisition of an amoeboid migratory phenotype. Moreover, TGF-beta upregulates RHOC and CDC42 after EGFR silencing, promoting Myosin II in amoeboid cells. Importantly, low EGFR combined with high TGFBI or RHOC/CDC42 levels confer poor patient prognosis. In conclusion, this work reveals a new tumour suppressor function for EGFR counteracting TGF-beta-mediated epithelial to amoeboid transitions in HCC, supporting a rational for targeting the TGF-beta pathway in patients with low EGFR expression. Our work also highlights the relevance of epithelial to amoeboid transition in human tumours and the need to better target this process in the clinic.
  •  
56.
  • Lotfi, Kourosh, 1966-, et al. (författare)
  • Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance
  • 2002
  • Ingår i: Cancer Letters. - 0304-3835 .- 1872-7980. ; 178:2, s. 141-149
  • Tidskriftsartikel (refereegranskat)abstract
    • Anthracycline antibiotics are widely used as anticancer agents. Idarubicin (4-demethoxydaunorubicin; Ida), a semisynthetic derivative of daunorubicin (Dnr) is more potent than the parent compound in vitro and in vivo. The equitoxic dose of Ida in patients is about one-fourth of that of Dnr. We compared these drugs regarding cytotoxicity, apoptosis induction, and resistance mechanisms in human leukaemic cell lines. Cytotoxicity was studied by means of the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide assay and drug-induced apoptosis by means of the Annexin V–fluorescein isothiocyanate method at similar intracellular concentrations (extracellular concentrations of 0.35 μM for Ida and 1 μM for Dnr). Ida was at least twice as potent as Dnr in MOLT-4, HL60, CEM, and K562 cell lines. It took 8 h for Ida to induce approximately 20% apoptosis, but at least 22 h for Dnr to reach 20% apoptosis at identical intracellular concentration. Ida induces a faster and higher apoptosis rate compared with Dnr. The human chronic myelogenous leukaemia cell line (K562) was selected for resistance to Dnr and Ida with and without verapamil (Ver). Continuous incubation with Dnr, but not with Ida, led to an increased mdr1 gene expression as assessed by real-time PCR. The development of mdr1 gene expression in Dnr-resistant cells could be reversed by the presence of Ver. Ver also reversed the cytotoxicity to Dnr, but not to Ida, in K562/Dnr cells. The results show that Ida is more effective than Dnr in inducing apoptosis and that there are differences in resistance mechanisms between the drugs.
  •  
57.
  •  
58.
  • Magnander, Karin, 1979, et al. (författare)
  • Biological consequences of formation and repair of complex DNA damage
  • 2012
  • Ingår i: Cancer letters. - : Elsevier BV. - 1872-7980 .- 0304-3835. ; 327:1-2
  • Tidskriftsartikel (refereegranskat)abstract
    • Endogenous processes or genotoxic agents can induce many types of single DNA damage (single-strand breaks, oxidized bases and abasic sites). In addition, ionizing radiation induces complex lesions such as double-strand breaks and clustered damage. To preserve the genomic stability and prevent carcinogenesis, distinct repair pathways have evolved. Despite this, complex DNA damage can cause severe problems and is believed to contribute to the biological consequences observed in cells exposed to genotoxic stress. In this review, the current knowledge of formation and repair of complex DNA damage is summarized and the risks and biological consequences associated with their repair are discussed.
  •  
59.
  • Mattsson, Johanna Sofia Margareta, 1985-, et al. (författare)
  • Prognostic impact of COX-2 in non-small cell lung cancer : a comprehensive compartment-specific evaluation of tumor and stromal cell expression
  • 2015
  • Ingår i: Cancer Letters. - : Elsevier BV. - 0304-3835 .- 1872-7980. ; 356:2, s. 837-845
  • Tidskriftsartikel (refereegranskat)abstract
    • Cyclooxygenase-2 (COX-2) is an enzyme that has been extensively investigated as a prognostic marker in cancer. In non-small cell lung cancer (NSCLC) previous results regarding the prognostic impact of COX-2 expression are inconsistent. Therefore we evaluated the association between transcript levels and overall survival in nine publicly available gene expression data sets (total n = 1337) and determined in situ compartment-specific tumor and stromal cell protein expression in two independent cohorts (n = 616). Gene expression did not show any correlation with clinical parameters or with overall survival. Protein expression in tumor and stromal cells did not correlate with any clinical parameter or with overall survival in one of the analyzed cohorts, while a significant association of high stromal expression with longer survival was observed in both univariate and multivariate analysis in the other cohort. Stromal expression of COX-2 has not been separately evaluated in NSCLC previously and may be a subject of further investigation, whereas the presented findings from this comprehensive compartment specific evaluation clearly reject the hypothesis of COX-2 tumor cell expression having a prognostic value in NSCLC. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
  •  
60.
  • Mi, Yushuai, et al. (författare)
  • miR-181a-5p promotes the progression of gastric cancer via RASSF6-mediated MAPK signalling activation
  • 2017
  • Ingår i: Cancer Letters. - : ELSEVIER IRELAND LTD. - 0304-3835 .- 1872-7980. ; 389, s. 11-22
  • Tidskriftsartikel (refereegranskat)abstract
    • We previously discovered that Ras association domain family member 6 (RASSF6) was downregulated and predicted poor prognosis in GC patients. However, the mechanisms of the down regulation of RASSF6 in GC remained unclear. Increasing evidence indicates that dysregulation of microRNAs promotes the progression of cancer through the repression of tumour suppressors. Here, we identified miR-181a-5p as a novel regulator of RASSF6 in GC. Functionally, ectopic expression or silencing of miR-181a-5p, respectively, promoted or inhibited GC cell proliferation, colony formation and cell cycle transition, as well as enhanced or prevented the invasion, metastasis of GC cells and epithelial to mesenchymal transition of GC cells in vitro and in vivo. Molecularly, miR-181a-5p functioned as an onco-miRNA by activating the RASSF6-regulated MAKP pathway. Overexpression or silencing of RASSF6 could partially reverse the effects of the overexpression or repression of miR-181a-5p on GC progress caused by activation of the MAKP pathway in vitro and in vivo. Clinically, high miR-181a-5p expression predicted poor survival in GC patients, especially combined with low RASSF6 expression. Collectively, we identified miR-181a-5p as an onco-miRNA, which acts by directly repressing RASSF6 in GC. (C) 2017 The Authors. Published by Elsevier Ireland Ltd.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 51-60 av 96
Typ av publikation
tidskriftsartikel (94)
forskningsöversikt (2)
Typ av innehåll
refereegranskat (96)
Författare/redaktör
Zhang, Z. (3)
Olsson, Håkan (2)
Pontén, Fredrik (2)
Ellmark, Peter (2)
Borrebaeck, Carl (2)
Wheelock, CE (2)
visa fler...
Abdiu, Avni, 1963- (2)
Wasteson, Åke, 1943- (2)
Walz, Thomas, 1960- (2)
Yu, Yang (1)
Huang, Y. (1)
Jiang, Y. (1)
Wang, X. (1)
Zhang, L. (1)
Zhu, Y. (1)
Bergh, J (1)
Aaltonen, Kristina (1)
Fernö, Mårten (1)
Wigerup, Caroline (1)
Hedenfalk, Ingrid (1)
Bexell, Daniel (1)
Hu, Y. (1)
Stål, Olle (1)
Ma, R. (1)
Leffler, Hakon (1)
Hammar, N (1)
Kumar, R. (1)
Larsson, Rolf (1)
Jerkeman, Mats (1)
Söderkvist, Peter (1)
Yano, Y (1)
Lund, Eiliv (1)
Overvad, Kim (1)
Boutron-Ruault, Mari ... (1)
Clavel-Chapelon, Fra ... (1)
Kaaks, Rudolf (1)
Boeing, Heiner (1)
Trichopoulou, Antoni ... (1)
Tumino, Rosario (1)
Sánchez, Maria-José (1)
Sund, Malin, 1972- (1)
Khaw, Kay-Tee (1)
Riboli, Elio (1)
Yang, L. (1)
Hansen, J (1)
Broberg Palmgren, Ka ... (1)
Mani, Katrin (1)
Giuliani, A. (1)
Wingren, Sten, 1950- (1)
Larsson, S-E (1)
visa färre...
Lärosäte
Karolinska Institutet (48)
Lunds universitet (30)
Linköpings universitet (17)
Uppsala universitet (10)
Kungliga Tekniska Högskolan (7)
Umeå universitet (6)
visa fler...
Örebro universitet (5)
Göteborgs universitet (2)
Stockholms universitet (1)
Mälardalens universitet (1)
Jönköping University (1)
visa färre...
Språk
Engelska (96)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (54)
Naturvetenskap (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy